Home Cart Sign in  
Chemical Structure| 878141-96-9 Chemical Structure| 878141-96-9

Structure of S1RA
CAS No.: 878141-96-9

Chemical Structure| 878141-96-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

S1RA is a potent and selective sigma-1 receptor (σ1R, Ki=17 nM) antagonist, showed good selectivity against σ2R (Ki > 1000 nM).

Synonyms: E-52862

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of S1RA

CAS No. :878141-96-9
Formula : C20H23N3O2
M.W : 337.42
SMILES Code : CC1=CC(OCCN2CCOCC2)=NN1C3=CC4=C(C=CC=C4)C=C3
Synonyms :
E-52862
MDL No. :MFCD25976945

Safety of S1RA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of S1RA

GPCR

Isoform Comparison

Biological Activity

Description
S1RA (E-52862) is a highly selective σ1 receptor (σ1R) antagonist with Kis of 17 nM and 23.5 nM for human σ1R and guinea pig σ1R, respectively. Its activity extends moderately towards the human 5-HT2B receptor with a Ki of 328 nM. This selectivity profile is complemented by its antinociceptive capabilities in models of neuropathic pain, demonstrating efficacy in preventing both mechanical and cold hypersensitivity in mice treated with Oxaliplatin[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
Androgen negative human prostate cancer cells DU145 4.0-5.5 µM 72 hours Inhibited the growth of DU145 tumor cells more effectively than the reference σ1 antagonists NE100 and S1RA ChemMedChem. 2022 Apr 5;17(7):e202100735

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Spinal cord contusion model Intraperitoneal injection 10, 20, 40, 60 mg/kg Single dose, evaluated after 30 minutes To evaluate the effect of S1RA on mechanical allodynia and thermal hyperalgesia after spinal cord contusion. Results showed that S1RA dose-dependently reversed both mechanical allodynia and thermal hyperalgesia. Sci Rep. 2018 Mar 1;8(1):3873
Sprague-Dawley rats Novel object recognition test Intraperitoneal injection 15 and 30 mg/kg Single dose, tested 30 minutes after administration Evaluated the role of S1RA in cognitive function; results showed S1RA as a σ1R antagonist did not improve learning and memory Pharmacol Rep. 2023 Oct;75(5):1291-1298
Mice Formalin-induced pain model Intraperitoneally (i.p.) 15 mg/kg Single administration, tested 30 min after administration Evaluated the analgesic effect of S1RA in the formalin-induced pain model, showing significant reduction in nociceptive response in the late phase Pharmaceuticals (Basel). 2023 Oct 17;16(10):1481
CD1 mice Partial sciatic nerve ligation-induced neuropathic pain model Intraperitoneal injection 16, 32, 64 mg/kg Single dose To evaluate the inhibitory effect of S1RA on neuropathic pain Br J Pharmacol. 2012 Aug;166(8):2289-306
Mice Σ2R−/− and σ1R−/− mice Intracerebroventricular injection 3 nmol Single administration S1RA increased the analgesic activity of morphine in both σ2R?/? and wild-type mice. Mol Brain. 2020 Nov 11;13(1):150
CD1 mice Permanent middle cerebral artery occlusion (pMCAO) model Intracerebroventricular (icv) or intravenous (iv) injection 3 nmol/mouse (icv) or 30 μg/mouse (iv) Up to 5 h before surgery and 3 h after ischaemic onset S1RA significantly reduced cerebral infarct volume, ameliorated neurological deficits, and suppressed the overexpression of MMP-9 and reactive astrogliosis. Mol Neurobiol. 2018 Jun;55(6):4940-4951
Rats Tail-flick test Intraperitoneal injection 40 mg/kg Single administration, observation time up to 300 minutes To evaluate the enhancement of systemic morphine antinociception by S1RA. Results showed that S1RA alone had no antinociceptive effect but significantly enhanced the antinociceptive effect of morphine when co-administered. Front Pharmacol. 2019 Apr 24;10:422
Mice CFA-induced periarticular inflammation model Subcutaneous injection 80 mg/kg Single or multiple administrations S1RA alone did not affect nociceptive heat pain or inflammatory tactile allodynia but partially reversed grip strength deficits. When combined with morphine, S1RA significantly enhanced morphine's analgesic effects on heat stimuli and inflammatory tactile allodynia but not on grip strength deficits. In morphine-tolerant animals, S1RA restored the analgesic effects of morphine. Front Pharmacol. 2019 Feb 22;10:136
Mice Spared nerve injury (SNI) model Subcutaneous injection 8–128 mg/kg Acute administration: single dose; Repeated administration: twice daily for 10 days S1RA alleviated SNI-induced neuropathic pain through σ1 receptor antagonism, with effects partially dependent on the endogenous opioid system. Front Pharmacol. 2019 Jun 12;10:613

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.96mL

0.59mL

0.30mL

14.82mL

2.96mL

1.48mL

29.64mL

5.93mL

2.96mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories